The US Food and Drug Administration (FDA) has approved Eisai and Biogen’s Supplemental Biologics License Application for once every four weeks intravenous (IV) maintenance dosing of LEQEMBI (lecanemab-irmb) for early Alzheimer’s disease (AD).
This decision may simplify the treatment process for patients and care partners.
LEQEMBI, designed for patients with mild cognitive impairment (MCI) or mild dementia due to AD, offers two dosing schedules. After an initial phase of once every two weeks for 18 months, patients can transition to the four-week dosing regimen…
